Quantum BioPharma Highlights Lucid-MS and unbuzzd Growth Opportunities in BioMedWire Podcast

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz outlined the company's growth prospects for its lead drug candidate Lucid-MS and its commercial product unbuzzd(TM). The discussion highlights Quantum's dual strategy of advancing a novel therapy for multiple sclerosis (MS) while generating revenue from a consumer health product.

Durkacz explained that Lucid-MS is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage—a mechanism he believes remains unmet by current treatments. The drug candidate has shown promise in preclinical models by preventing and reversing myelin degradation, the underlying cause of MS. Quantum is preparing for a Phase 2 clinical trial, which will be the first study to evaluate Lucid-MS in multiple sclerosis patients, following Phase 1 testing in healthy volunteers. This progression marks a significant milestone for the company and could address a critical gap in MS care.

In parallel, Durkacz highlighted unbuzzd(TM), a commercial alcohol metabolism product designed to accelerate blood alcohol metabolism. Already available in the U.S. market, unbuzzd represents a tangible revenue stream for Quantum. The company retains a 19.84% ownership stake in Unbuzzd Wellness Inc., the entity that markets the product, as well as royalty payments: 7% of sales until payments total $250 million, then 3% in perpetuity. This structure provides ongoing income without diluting Quantum's focus on its pharmaceutical pipeline.

The podcast appearance underscores the importance of Quantum's diversified approach. While many biotech firms rely solely on drug development, Quantum's combination of a high-potential MS therapy and a consumer product offers a balanced risk profile. The upcoming Phase 2 trial for Lucid-MS is a pivotal event that could validate its mechanism and attract partnerships or investment. Meanwhile, unbuzzd provides near-term revenue and market presence, potentially funding further research.

Investors and industry observers will watch closely as Quantum moves Lucid-MS into patient trials. If successful, the drug could become a cornerstone treatment for MS, a market with significant unmet need. The company's ability to simultaneously commercialize unbuzzd demonstrates operational agility. For more information on Quantum BioPharma and its developments, visit the company's newsroom at https://ibn.fm/QNTM.